Despite having been identified as the organism that causes tuberculosis in 1882,
Mycobacterium tuberculosis has managed to still evade our understanding of the protective …

To eliminate tuberculosis globally, a new, effective, and affordable vaccine is urgently
needed, particularly for use in adults and adolescents in low-income and middle-income …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Tuberculosis is the leading infectious disease killer globally due to a single pathogen.
Despite wide deployment of standard drug regimens, modern diagnostics and a vaccine …

Bacillus Calmette-Guerin (BCG) is an attenuated bacterial vaccine used to protect against
Mycobacterium tuberculosis (Mtb) in regions where infections are highly prevalent. BCG is …

Despite co-evolving with humans for centuries and being intensely studied for decades, the
immune correlates of protection against Mycobacterium tuberculosis (Mtb) have yet to be …

To fight tuberculosis, better vaccination strategies are needed. Live attenuated
Mycobacterium tuberculosis-derived vaccine, MTBVAC, is a promising candidate in the …

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the
global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines …

Regardless of the eventual site of disease, the point of entry for Mycobacterium tuberculosis
(M. tb) is via the respiratory tract and tuberculosis (TB) remains primarily a disease of the …

Background Mycobacterium tuberculosis is the main causative agent of tuberculosis. BCG,
the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis …